Loading...
XSTOBIOSGN
Market cap12mUSD
Dec 23, Last price  
0.57SEK
1D
14.40%
1Q
-10.34%
IPO
-92.16%
Name

Biosergen AB

Chart & Performance

D1W1MN
XSTO:BIOSGN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
1,314,2894,432,0008,573,00000
Net income
-27m
L-20.28%
-5,420,162-7,222,000-34,558,000-33,913,000-27,037,000
CFO
-33m
L+10.74%
-2,314,424-4,584,000-37,749,000-29,441,000-32,603,000

Profile

Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
URL
https://biosergen.net/
IPO date
Jun 24, 2021
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
8,573
93.43%
Cost of revenue
456
280
40,822
Unusual Expense (Income)
NOPBT
(456)
(280)
(32,249)
NOPBT Margin
Operating Taxes
(135)
240
Tax Rate
NOPAT
(456)
(145)
(32,489)
Net income
(27,037)
-20.28%
(33,913)
-1.87%
(34,558)
378.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,297
37,118
58,825
BB yield
-13.40%
-67.00%
-20.29%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(1,883)
(29,342)
(21,665)
Cash flow
Cash from operating activities
(32,603)
(29,441)
(37,749)
CAPEX
Cash from investing activities
Cash from financing activities
5,297
37,118
71
FCF
(689)
(145)
(43,413)
Balance
Cash
1,883
29,342
21,665
Long term investments
Excess cash
1,883
29,342
21,236
Stockholders' equity
1,266
22,815
20,253
Invested Capital
850
(22)
(21)
ROIC
686.16%
158,243.63%
ROCE
EV
Common stock shares outstanding
44,927
52,764
53,490
Price
0.88
-16.19%
1.05
-80.63%
5.42
 
Market cap
39,535
-28.64%
55,403
-80.89%
289,915
 
EV
37,652
26,061
268,250
EBITDA
(456)
(280)
(32,249)
EV/EBITDA
Interest
54
240
Interest/NOPBT